| Aspirin | coronary artery disease, in all type of patients | vs placebo | cardiovascular events by 29% suggested Cardiovascular death by 27% suggested Fatal MI by 58% suggested Non fatal MI by 30% suggested | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| cardiovascular events | 0.71 [0.55 0.92] | p=0.04 | 0 | 2035 | 1 | SAPAT, | | Cardiovascular death | 0.73 [0.60 0.90] | p=0.04 | 0 | 6600 | 5 | CDPA, Vogel, PARIS, JAMIS, SAPAT, | | Coronary event | no data | | Non vascular death | 1.66 [0.78 3.54] | p=1.00 | 0 | 2035 | 1 | SAPAT, | | Fatal MI | 0.42 [0.22 0.80] | p=0.04 | 0 | 1966 | 2 | Vogel, GAMIS, | | Non fatal MI | 0.70 [0.60 0.82] | p=0.04 | 0 | 11750 | 7 | CDPA, Vogel, AMIS, GAMIS, PARIS, JAMIS, SAPAT, | | All cause death | 0.90 [0.80 1.01] | p=1.00 | 0 | 12636 | 8 | CDPA, Cardiff I, Cardiff II, Vogel, AMIS, GAMIS, PARIS, JAMIS, | | Non fatal stroke | 0.79 [0.44 1.41] | p=1.00 | 0 | 2035 | 1 | SAPAT, | | Major bleeding | no data | | Adverse events | no data | | Major bleeding | no data | | stroke (fatal and non fatal) | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| CDPA, 1976 | Aspirin (324 mg) 3x/d | Placebo | MI survivors | | Cardiff I, 1974 | Aspirin (300 mg) 1x/d | Placebo | MI survivors | | Cardiff II, 1979 | Aspirin (300 mg) 3x/d for one year | Placebo | patients with myocardial infarction | | Vogel, 1979 | Aspirin (1.5 g daily) on an average period of 22 months
| Placebo
| | | AMIS, 1980 | Aspirin (500 mg) 2x/d for at least 3 years | Placebo | men and women who had had a documented myocardial infarction | | GAMIS, 1980 | Aspirin (500 mg) 3x/d for 2 years | Placebo | patients who had survived a myocardial infarction for 30-42 days | | PARIS, 1980 | Aspirin (324 mg) 3x/d | Placebo | patients who had recovered from myocardial infarction | | JAMIS, 1999 | Aspirin (81 mg) 1x/d | No antiplatelets | patients with AMI within 1 month from the onset of symptoms | | SAPAT, 1992 | aspirin 75 mg daily | placebo | patients with stable chronic angina pectoris |
| |
| Clopidogrel | coronary artery disease, in all type of patients | vs aspirin | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| cardiovascular events | 0.90 [0.60 1.35] | p=1.00 | 0 | 1001 | 1 | ASCET, | | Cardiovascular death | no data | | Coronary event | no data | | Non vascular death | no data | | Fatal MI | 0.71 [0.50 1.00] | p=1.00 | 0 | 19185 | 1 | CAPRIE, | | Non fatal MI | 0.85 [0.71 1.00] | p=1.00 | 0 | 19185 | 1 | CAPRIE, | | All cause death | 0.98 [0.87 1.10] | p=1.00 | 0 | 19185 | 1 | CAPRIE, | | Non fatal stroke | no data | | Major bleeding | no data | | Adverse events | no data | | Major bleeding | no data | | stroke (fatal and non fatal) | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| CAPRIE, 1996 | Clopidogrel (75 mg) 1x/d for a minimum of one year and a maximum of 3 years | Aspirin (325 mg) 1x/d | patients with atherosclerotic vascular disease manifested as either recent ischaemic stroke, recent myocardial infarction, or symptomatic peripheral arterial disease | | ASCET, | clopidogrel 75 mg once daily for two years | Aspirin 160 mg once daily for two years | patients with documented coronary heart disease and treated with aspirin |
| |
| Dipyridamol | coronary artery disease, in all type of patients | vs control | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| cardiovascular events | 1.37 [0.40 4.74] | p=1.00 | 0 | 143 | 3 | Atlanta (Sbar), Becker, Wirecki, | | Cardiovascular death | 2.21 [0.30 16.24] | p=1.00 | 0 | 143 | 3 | Atlanta (Sbar), Becker, Wirecki, | | Non vascular death | 0.98 [0.10 9.64] | p=1.00 | 0 | 143 | 3 | Atlanta (Sbar), Becker, Wirecki, | | Non fatal MI | 0.80 [0.20 3.18] | p=1.00 | 0 | 143 | 3 | Atlanta (Sbar), Becker, Wirecki, | | Non fatal stroke | 1.57 [0.19 13.12] | p=1.00 | 0 | 143 | 3 | Atlanta (Sbar), Becker, Wirecki, | | Major bleeding | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| Atlanta (Sbar), 1967 | dipyridamole 150mg daily | placebo | patients with angina pectoris | | Becker, 1967 | dipyridamole 225mg daily | placebo | | | Wirecki, 1967 | dipyridamole 150mg daily | placebo | patients with angina pectoris |
| |
| Dipyridamol | | vs placebo | Non fatal MI by 31% suggested stroke (fatal and non fatal) by 39% suggested | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| cardiovascular events | no data | | Cardiovascular death | 0.88 [0.70 1.11] | p=1.00 | 0 | 4344 | 2 | PARIS, PARIS-II, | | Coronary event | no data | | Non vascular death | no data | | Fatal MI | no data | | Non fatal MI | 0.69 [0.54 0.88] | p=0.04 | 0 | 4344 | 2 | PARIS, PARIS-II, | | All cause death | 0.92 [0.74 1.15] | p=1.00 | 0 | 4344 | 2 | PARIS, PARIS-II, | | Non fatal stroke | no data | | Major bleeding | no data | | Adverse events | no data | | Major bleeding | no data | | stroke (fatal and non fatal) | 0.61 [0.38 0.99] | p=0.04 | 0 | 4344 | 2 | PARIS, PARIS-II, |
| Trial | Studied treatment | Control | Patients |
|---|
| PARIS, 1980 | Aspirin (324 mg) + dipyridamole (75 mg) 3x/d | Placebo | patients who had recovered from myocardial infarction | | PARIS-II, 1986 | Aspirin (330 mg) + dipyridamole (75 mg) 3x/d | Placebo | patients who had recovered from myocardial infarction, suffered from 4 weeks to 4 months previously | | Igloe, 1970 | Dipyridamole 200mg daily | placebo | patients with angina pectoris | | Zion, 1961 | Dipyridamole 37.5mg | placebo | patients with angina pectoris | | Kinsella, 1962 | dipyridamole 37.5 mg and 100mg daily | placebo | | | Leiberman, 1964 | dipyridamole 100mg daily | placebo | | | Dewar, 1961 | Dipyridamole 100mg daily | placebo | patients with angina pectoris | | Neumann, 1964 | dipyridamole 150mg daily | placebo | elderly with precordial pain | | Foulds, 1960 | Dipyridamole 200mg daily | placebo | patients with angina pectoris |
| |
| Dipyridamol | | vs aspirin | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Cardiovascular death | 0.99 [0.70 1.38] | p=1.00 | 0 | 1620 | 1 | PARIS, | | Coronary event | 1.05 [0.80 1.36] | p=1.00 | 0 | 1620 | 1 | PARIS, | | Fatal MI | no data | | Non fatal MI | 1.14 [0.79 1.66] | p=1.00 | 0 | 1620 | 1 | PARIS, | | All cause death | 1.02 [0.75 1.40] | p=1.00 | 0 | 1620 | 1 | PARIS, | | Adverse events | no data | | Major bleeding | no data | | stroke (fatal and non fatal) | 1.11 [0.45 2.75] | p=1.00 | 0 | 1620 | 1 | PARIS, |
| Trial | Studied treatment | Control | Patients |
|---|
| PARIS, 1980 | Aspirin (324 mg) + dipyridamole (75 mg) 3x/d | Aspirin (324 mg) 3x/d | patuents who had recovered from myocardial infarction |
| |
| Ticlopidine | coronary artery disease, in all type of patients | vs placebo | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| cardiovascular events | 0.81 [0.02 43.03] | p=1.00 | 0 | 38 | 1 | Berglund, | | Cardiovascular death | 0.81 [0.02 43.03] | p=1.00 | 0 | 38 | 1 | Berglund, | | Non vascular death | 0.81 [0.02 43.03] | p=1.00 | 0 | 38 | 1 | Berglund, | | Non fatal MI | 0.81 [0.02 43.03] | p=1.00 | 0 | 38 | 1 | Berglund, | | Non fatal stroke | 0.81 [0.02 43.03] | p=1.00 | 0 | 38 | 1 | Berglund, | | Major bleeding | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| Berglund, 1985 | ticlopidine 500 mg daily | placebo | middle-aged men with stable incapacitating angina pectoris |
| |
